drugset / Trial / NCT00334074

Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS

NCT00334074

Phase 2 Completed 30 enrolled Baylor Research Institute
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to to determine the safety and effectiveness of therapeutic combination - Clofarabine and Cytarabine for the treatment of AML and MDS.

Timeline

Start
2005-08
Primary completion
2007-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Clofarabine Other / unclassified 40 mg/m2 Intravenous
Subject Cytarabine Small molecule 1000 mg/m2 Intravenous